The role of therapy in impairing quality of life in dermatological patients: a multinational study by Balieva, F et al.
1 
 
Title: The role of therapy in impairing quality of life in dermatological patients: a 
multinational study 
Short title: Burden of treatment in skin disease 
Flora N Balieva1, Andrew Y Finlay2, Jörg Kupfer3, Lucia Tomas Aragones4, Lars Lien5,6, 
Uwe Gieler7, Francoise Poot8, Gregor BE Jemec9, Laurent Misery10, Lajos Kemeny11, 
Francesca Sampogna12, Henriët van Middendorp13, Jon Anders Halvorsen14,15, Thomas 
Ternowitz1, Jacek C Szepietowski16, Nikolay Potekaev17,18, Servando E Marron19, Ilknur K 
Altunay20, Sam S Salek21,22, Florence J Dalgard5,23 
1Department of Dermatology, Stavanger University Hospital, Stavanger, Norway 
2Department of Dermatology and Wound Healing, Cardiff University School of Medicine, 
Cardiff, United Kingdom 
3Institute of Medical Psychology, Justus Liebig University, Giessen, Germany 
4Department of Psychology, University of Zaragoza, Aragon Health Sciences Institute, 
Zaragoza, Spain 
5Innlandet Hospital Trust, Brumundal, Norway 
6Hedmark University College, Elverum, Norway 
7Department of Dermatology, Justus Liebig University, Giessen, Germany 
8Department of Dermatology, ULB-Erasme Hospital, Brussels, Belgium 
9Department of Dermatology, Zealand University Hospital, Roskilde, Denmark 
10Department of Dermatology, University Hospital of Brest, Brest, France 
11Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary 
12Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata, Rome, Italy 
13Health, Medical and Neuropsychology Unit, Faculty of Social and Behavioural Sciences, 
Leiden University, Leiden, The Netherlands 
14Department of Dermatology, Oslo University Hospital, Rikshospitalet 
15University of Oslo, Oslo, Norway 
2 
 
 16Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 
Wroclaw, Poland 
17Moscow Scientific and Practical Centre of Dermatovenereology and Cosmetology 
18Department of Dermatology, Russian National Research Medical University Pirogov, 
Moscow, Russia 
19Department of Dermatology, Royo Villanova Hospital. Aragon Health Sciences Institute, 
Zaragoza, Spain 
20Department of Dermatology, Sisli Etfal Teaching and Research Hospital, Istanbul, Turkey 
21School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom 
22Institute for Medicines Development Cardiff, United Kingdom 
23Department of Dermatology and Venereology, Skåne University Hospital, Lund University, 
Malmö, Sweden 
 
CONFLICTS OF INTEREST 
AYF is joint copyright owner of the DLQI. Cardiff University and AYF receive royalties 
(though not from this study). 
  
3 
 
ABSTRACT 
Skin disease and its therapy affect health related quality of life (HRQoL). We aimed to 
measure the burden caused by the dermatological therapy in 3846 patients from 13 European 
countries. Adult outpatients completed questionnaires, including the Dermatology Life 
Quality Index (DLQI) which has a therapy impact question. Therapy issues were reported by 
a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), 
hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in 
HRQoL attributable to therapy, as percentage of the total DLQI, adjusted for confounders was 
seen in blistering conditions (10.7%), allergic/drug reactions (10.2%), psoriasis (9.9%), 
vasculitis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers 
(8.5%). In skin cancer, although having less impact on HRQoL, the reduction due to therapy 
was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the 
burden of dermatological treatment should be considered when planning therapy and 
designing new dermatological therapies. 
Acta Dermato-Venereologica 
Flora Balieva 
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Pb. 8100, 4068 Stavanger, Norway 
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INTRODUCTION 
Topical and other dermatological therapies can add to skin disease burden, as they may be 
time-consuming, messy, intervene with clothing choice and impact health related quality of 
life (HRQoL) in ways unique to the skin (1, 2). This contrasts with the relatively low burden 
of oral therapy given for other diseases (3), where for most, oral medication becomes routine. 
However, even systemic dermatological medications such as cytotoxic drugs, corticosteroids, 
retinoids, intravenous or injected biologics, may have an associated burden. Topical and 
injection routes of drug administration show lowest convenience and global satisfaction (4). 
Impairment of HRQoL due to dermatologic therapy is little explored, even though the burden 
caused by skin disease treatment is very important, both to patients and because it contributes 
to poor adherence (5). 
Most generic HRQoL measures were developed without including skin diseases. It is 
therefore unsurprising that they miss the burden experienced by dermatological patients. In 
measures designed for use across skin diseases, only the Dermatology Life Quality Index 
(DLQI) includes a question concerning the impact of treatment on everyday life (6). 
The aim of this study was to measure how the therapy of skin disease contributes to reducing 
HRQoL in outpatients across Europe. 
METHODS 
Data was used from a cross-sectional multicentre study on patients recruited from 15 
dermatological outpatient clinics in 13 European countries: details have been previously 
reported (7). The study was approved by the Regional Committee for Medical Research 
Ethics in Norway. Separate ethical approvals were obtained where necessary. The study was 
conducted in accordance with the Declaration of Helsinki. 
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Consecutive patients, age above 18 years, understanding the local language and not suffering 
from severe mental disease were invited to participate on random days, giving written 
consent. Participants completed questionnaires on sociodemographics (sex, age, ethnicity, 
education, marital and socioeconomic status), the DLQI and other questionnaires (7-11). 
Patients were examined by the dermatologist, who recorded comorbidities: diabetes mellitus, 
cardiovascular, chronic respiratory, rheumatologic or other disease. Workers from each 
hospital’s service division were invited to participate as control. 
The DLQI, a 10 item questionnaire, was used to assess HRQoL impairment. Question 10, 
which concerns the impact of therapy, was used to assess how treatment impaired HRQoL: 
‘…how much of a problem has the treatment for your skin been, for example by making your 
home messy, or by taking up time?’ with possible answers “very much” (scored 3), “a lot” 
(2), “a little” (1) or “not at all/not relevant” (0). 
The DLQI was not designed for use by healthy individuals. Patients with nevi (n=192) served 
as ‘healthy’ controls since there were no significant differences between nevi and the healthy 
controls (7, 8). 
Statistical analysis 
Data from all centres were merged. Diagnoses were organized into 35 disease groups (8, 12). 
SPSS 24 software was used. Frequencies and means for patient and control characteristics 
were calculated. 
The answers to DLQI question 10 were dichotomized into ‘no impairment’ (0) or ‘impaired’ 
(1, 2 or 3) when calculating frequencies of positive answers. 
For each diagnosis mean scores for question 10 and total DLQI were calculated.  Their 
relationship was calculated as (
𝑚𝑒𝑎𝑛 𝑠𝑐𝑜𝑟𝑒 𝑄𝑢𝑒𝑠𝑡𝑖𝑜𝑛 10
𝑚𝑒𝑎𝑛 𝑡𝑜𝑡𝑎𝑙 𝐷𝐿𝑄𝐼 𝑠𝑐𝑜𝑟𝑒
x100), denoted as Q10%. 
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Comparisons between patients with nevi and healthy controls were performed with the t-test 
for continuous variables (age) and the x2-test for categorical variables (sex, marital status, 
socioeconomic status, comorbidities, economic difficulties, stress, depression and anxiety (7)) 
and linear (EQ-VAS) and logistic regressions (EQ5D) for comparing HRQoL outcomes (8). 
Linear regression was performed to analyze Q10% for each diagnosis adjusting for age, sex, 
socioeconomic status and comorbidity with ‘nevi’ as controls. 
A search for publications on therapy issues in dermatology using DLQI or other instruments 
was performed using MEDLINE, EMBASE and Cochrane Library following standard search 
strategies. Search terms and medical descriptors (MeSH) included skin disease, dermatosis, 
dermatoses, quality of life, DLQI, skin therapy, topical therapy, photodynamic therapy, 
cryotherapy, cryosurgery, cryoablation, laser, phototherapy, photochemotherapy, UVB, UVA, 
UVA1, PUVA, RePUVA, topical drug administration, parenteral administration, biological 
therapy, TNF-α inhibitors, infusion therapy, skin cancer therapy, surgical dermatological 
therapy. 
RESULTS 
Participants 
There were 4010 participants and 1359 healthy controls. Comparative details are previously 
published (7-11) and briefly given in Supplementary Table I. 
DLQI data 
There were 3846 (96%) valid answers to DLQI and 5.2% of those had a DLQI>20 (extremely 
large effect on HRQoL). One fifth (20.3%) experienced at least a very large effect (DLQI>11) 
and 44.9% had a DLQI>6, meaning at least a moderate effect on HRQoL (13) caused by their 
skin disease (Supplementary Table II). 
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The total patient population (n=3846) had a mean DLQI score of 6.73 (Standard Deviation 
(SD) 6.8), meaning moderately impaired HRQoL. Except for nevi, no skin disease had a mean 
score <2, so all had at least a small effect on patients’ HRQoL. Twenty-seven of the 35 (77%) 
skin conditions had mean DLQI scores >5, indicating at least a moderate effect on a patient’s 
life (Supplementary Table III). 
Higher DLQI values, indicating higher impairment, were seen in females, younger age 
groups, patients with comorbidities and lower socioeconomic status. 
Therapy impact data (DLQI question 10) 
Question 10 in the DLQI addresses therapy related issues. Number of patients answering with 
‘a little’, ‘a lot’ or ‘very much’, i.e. other than ‘no impact/not relevant’, are given in Fig.1. 
More than half of the patients with atopic dermatitis (63.4%), prurigo (60.7%), psoriasis 
(54.4%), HS (54.3%) and blistering disorders (53%) answered positively. Fifteen of 32 skin 
conditions had >33.3% patients scoring positively. 
The mean scores with SD for question 10 and Q10% for each diagnosis are presented in Table 
I. There are no existing cut-off values for interpreting results from single questions of the 
DLQI and isolated values may not give a clear perspective as to how big the impact is. Q10% 
is not a standardized method for interpreting DLQI data but does give perspective on how 
therapy issues relate to the total HRQoL impairment. Table I lists the diseases in descending 
values according to Q10%, adjusted for age, sex, socioeconomic status and comorbidity. The 
positive standardized β coefficients for all diseases denote influence of therapy on HRQoL 
even when adjusted. For many diseases the β coefficient was relatively high, indicating 
robustness of the presented results. 
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When assessing Q10%, males and older patients showed more impairment, the reverse of 
what was seen for total mean DLQI. The impairment was highest in patients with 
comorbidities or of low socioeconomic status. 
When considering the impact of therapy on HRQoL, highest mean scores and most positive 
answers to question 10 were seen in diseases which commonly affect large areas of the skin 
(e.g. atopic dermatitis, psoriasis, allergic/drug/phototoxic conditions, prurigo, 
papulosquamous diseases, eczemas, connective tissue disease and vitiligo), as well as diseases 
accompanied by blisters/erosions, ulceration or crusting (blistering diseases, venous leg ulcer, 
vasculitis, immunological ulcers and oral diseases) and pruritic dermatoses (prurigo, urticaria 
and pruritus) (Table I, Figure 1). 
Q10% reveals which diagnostic groups are most affected by therapy relative to their total 
HRQoL impairment. Blistering conditions showed the highest value (10.7), followed by 
allergic, drug, phototoxic/-allergic reactions (10.2) and psoriasis (9.9), a ranking that differs 
from total mean DLQI values (Supplementary Table III). This gives insight into the true extra 
burden of therapy for different diseases. 
HS, prurigo, pruritus and urticaria show highest impairment when mean DLQI scores are 
evaluated but drop in ranking when therapy is assessed. Likewise, acne, rosacea and 
psychodermatological conditions, scoring among the average impaired as measured by mean 
DLQI scores, were some of the least affected by therapy. Conversely, blistering conditions, 
non-melanoma skin cancer (NMSC), actinic keratoses (AK), allergic/drug reactions, vasculitis 
and venous leg ulcers rank higher when evaluated according to therapy-related impairment. 
DISCUSSION 
Using a dermatology-specific measure we identified the extent of the reduced HRQoL 
associated with therapy.  For several diseases, patients experience a high burden associated 
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with therapy (blistering conditions, allergic/drug reactions, psoriasis, vasculitis, vitiligo and 
venous leg ulcers). Ranking the diseases according to what percentage of the burden is caused 
by therapy gives new insight into this specific impairment for the separate diagnoses. 
Most skin diseases are treated with topical therapy.  However dermatological treatments 
include oral therapy, phototherapy, photodynamic therapy, lasers, cryotherapy, intralesional 
and surgical procedures and also parenteral administrations, which may be painful, time-
consuming or cause infusion reactions. The use of these specific dermatological medications 
and therapeutic approaches presents issues and challenges unique to skin disease. 
Generic HRQoL measures have been developed without specific reference to impact of 
therapy for skin disease (Table II). Assessment may therefore be inaccurate if this burden 
experienced by dermatological patients is missed. There are no questions related to the impact 
of therapy in the most commonly used generic measures. However, the generic measures 
Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) (3) and Treatment 
Satisfaction Questionnaire for Medication (TSQM) (4) are designed to address issues with 
medication, but are little used in dermatology. The DLQI is the only non-disease specific 
dermatological measure that addresses therapy burden (Table II), but although the DLQI is 
the most widely used measure in dermatology (14) the issue of therapy is little explored. 
There are very few studies evaluating the contribution of therapy to impairment of HRQoL. In 
three studies (15-17) the generic instrument SF-36 was used in random samples of the 
population. A large proportion of patients reported dermatological problems and those using 
topical therapies on prescription showed greater impairment of HRQoL than those not using 
topical prescription medicines (15).  
An overview of the most relevant results for several diagnoses is given below: 
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Blistering diseases showed the highest impairment due to therapy and positive standardized β 
values as high as 0.5, in support of the high impairment being caused by the disease and its 
therapy and not because of the age, sex, comorbidity and socioeconomic status of the patients. 
HS results in severely impaired HRQoL (18, 19), has the highest mean DLQI, but scores for 
Q10% are low. Studies of the same data set rank HS patients with some of the lowest HRQoL 
(8), highest risk for psychiatric comorbidity (7, 20) and impairment in sexual life (9). Despite 
very high impairment of HRQoL, therapy contributes little to this burden. 
Atopic dermatitis and psoriasis rank highly when mean DLQI, positive answers to therapy 
issues or Q10% are evaluated, suggesting that these patients suffer equally from all aspects of 
HRQoL, including therapy. 
Diseases affecting small areas of the body, such as facial dermatoses (seborrhoeic dermatitis, 
rosacea and acne) as well as psychodermatological conditions rank lower on therapy relative 
to the total DLQI than might be expected, demonstrating that it is the disease itself and not the 
therapy that is the driving cause of  HRQoL impairment. Treating these conditions adequately 
should alleviate the patient’s experienced burden without additional impairment. 
In contrast, patients with AK, NMSC, allergic/drug reactions, scars/fibrosis and morphea, 
who do not report severe impairment of HRQoL as measured by the mean DLQI, rank high in 
impairment when assessing therapy as a percentage of this total score. AK and NMSC do not 
apparently have a high impact on HRQoL, nor psychiatric comorbidity (7, 8, 20), but score 
relatively worse when therapy is assessed, ranking them higher than HS and several other 
diseases.  
Studies evaluating the burden caused by AK and/or NMSC have shown low impact on 
HRQoL of these diseases (21-24), raising the possibility that currently available measures 
may be missing therapy issues and that there may be a need for a skin cancer specific HRQoL 
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measure. Existing disease-specific instruments do not include therapy questions (22, 25) 
(Table II). 
Burdensome treatments have a negative effect on adherence to therapy (5) and can be the 
reason for undertreatment and relapse of disease. Measuring HRQoL without taking into 
account therapy issues may not give the true extent of suffering that dermatological patients 
experience. On the other hand, knowing which diseases have the highest potential to cause 
therapy issues can alert clinicians to which patients need a different approach, by giving them 
better information, providing a variety of options, offering training in therapy application or at 
least acknowledging the issue. 
When developing clinical guidelines in dermatology, optimization of therapy and minimising 
burden of treatment should be considered. Developers of HRQoL instruments should pay 
attention to therapy issues when measuring HRQoL in some specific diagnoses such as skin 
cancer, as this burden may go undetected using current available measures (7, 8, 20-23). 
Strengths and limitations 
The large amount of patients in this study, the unbiased selection of participants and adjusting 
for confounding factors resulted in robust data on therapy as a factor contributing to 
impairment in HRQoL. Similar studies on therapeutic issues are lacking and studies using 
DLQI typically have no healthy control group. 
One potential weakness is in the detail of the wording of the DLQI question 10: “(…by 
making your home messy, or by taking up time)” which might bias the respondents into only 
considering topical therapy. However, the main question itself is neutral on this point “…how 
much of a problem has the treatment for your skin been…”. 
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Detailed information on all treatments used by our patients was not systematically obtained. 
The presented data evaluate therapy issues on a general basis. Further studies evaluating 
specific dermatological treatments are warranted. 
Although we refer to data from each country, the data was based on one centre from each 
country (apart from Italy and Norway). The recruitment centres may not have been 
representative of clinical practice across each country. There were large differences between 
countries in scores assessing impairment which cannot be readily explained. The cross-
cultural issue is one that is of relevance to all HRQoL measures (26). The same limitation 
may apply when comparing diseases (27). The cultural and language factors leading to these 
differences are not fully understood, though they should be taken into account when making 
any cross-cultural comparisons and when using HRQoL data as a guide to optimal health 
policies and creating optimal treatment guidelines. Analysis of the source for country 
differences may be able to serve as a guide to optimal health policies and creating optimal 
treatment guidelines. 
Conclusion 
Treatments for skin diseases contribute to the burden on HRQoL. For some diagnoses, 
therapy may have a larger impact than was previously known, but we also identify diseases 
that to a lesser degree are affected by therapy. Older, male patients with lower socioeconomic 
status and comorbidities suffer more from therapy issues. Our study highlights new aspects to 
HRQoL that may have been overlooked previously. Clinicians are made aware of the 
importance in addressing therapy issues and promoting adherence to therapy, pharmaceutical 
companies to ease of use of their products. Developers of HRQoL instruments should 
consider including therapy related questions. The ultimate goal would be to reduce the burden 
of skin disease and promote adherence. 
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Table I. Effect of treatment on DLQI. Ranking according to the percentage of Question 10 of the DLQI (therapy issues) to 
the mean total DLQI (Q10%) for diagnoses with at least 20 valid answers (hyperhidrosis (12), nail diseases (17) and 
granuloma annulare (13) excluded). Linear regression (standardized β) with ‘nevi’ as a ‘healthy’ control group, adjusting 
for age, sex, socioeconomic status and comorbidity (diabetes mellitus, cardiological, respiratory, rheumatologic or other 
disease). Mean DLQI and mean score to Question 10 (therapy issues) and standard deviation (SD) given in separate columns. 
  
         
Diagnosis Q10%a 
Standar-
dized β 
Question 10 
Mean (SD) 
Mean DLQI 
(SD) 
Valid N/ 
Valid N βb 
 All patientsc 7.73 0.06 0.52 (0.8) 6.73 (6.8) 3846/3553 
1 Blistering conditions 10.71 0.47 0.92 (1.0) 8.59 (7.4) 66/49 
2 Allergic, drug, phototoxic/-allergic reactions 10.21 0.39 0.54 (0.8) 5.29 (4.3) 24/21 
3 Psoriasis 9.85 0.19 0.90 (1.0) 9.14 (7.6) 660/615 
4 Vasculitis and immunological ulcersd 8.78 0.28 0.62 (0.9) 7.06 (6.1) 67/60 
5 Atopic dermatitis 8.67 0.33 1.0 (0.9) 11.53 (7.2) 172/150 
6 Vitiligo 8.62 0.36 0.33 (0.6) 3.83 (3.7) 24 
7 Venous leg ulcers 8.47 0.27 0.80 (1.0) 9.45 (7.3) 113/87 
8 Other hair disorderse 8.38 0.27 0.42 (0.8) 5.01 (5.4) 82/76 
9 Prurigo 8.13 0.33 0.93 (0.9) 11.44 (8.2) 27/24 
10 Scars, fibrosis of the skin, morphea 8.11 0.24 0.43 (0.9) 5.3 (4.8) 27 
11 Papulosquamous skin diseasesf 7.69 0.21 0.49 (0.8) 6.37 (6.4) 113/103 
12 Connective tissue disease 7.43 0.20 0.58 (0.9) 7.81 (7.0) 91/74 
13 Oral conditionsg 7.39 0.24 0.50 (0.8) 6.77 (6.6) 26 
14 Eczema 7.36 0.21 0.62 (0.9) 8.42 (7.2) 234 
15 Urticaria 7.09 0.35 0.68 (0.9) 9.59 (6.7) 69/60 
16 Hand eczema 7.05 0.18 0.60 (0.9) 8.51 (7.2) 156/146 
17 Alopecia areata 6.99 0.18 0.39 (0.8) 5.58 (6.8) 31/30 
18 Pruritus 6.84 0.24 0.75 (1.0) 10.97 (7.1) 60/58 
19 Non-melanoma skin cancer and actinic keratosis  6.75 0.11 0.16 (0.5) 2.37 (5.0) 401/372 
20 Genital (non-venereal)h 6.36 0.22 0.56 (0.8) 8.81 (6.4) 32/30 
21 Otheri 6.15 0.20 0.39 (0.7) 6.34 (6.6) 96/67 
22 Hidradenitis suppurativa 6.14 0.24 0.78 (0.8) 12.7 (7.6) 46/44 
23 Infections of the skin 6.09 0.21 0.38 (0.8) 6.24 (5.8) 253/244 
24 Benign skin tumours 5.51 0.09 0.15 (0.5) 2.72 (3.7) 159/154 
25 Lichen planus 5.42 0.07 0.33 (0.7) 6.09 (5.4) 46/41 
26 Seborrhoeic dermatitis  5.41 0.23 0.34 (0.6) 6.28 (4.4) 75/74 
27 Psychodermatological conditions  5.41 0.14 0.46 (0.8) 8.5 (7.1) 34 
28 Acne 4.99 0.16 0.31 (0.6) 6.21 (5.2) 234/228 
29 Rosacea 4.66 0.09 0.25 (0.6) 5.37 (5.3) 75/68 
30 Nevi 4.61 - 0.07 (0.3) 1.52 (2.9) 186 
31 Malignant melanoma 4.41 0.03 0.12 (0.4) 2.72 (4.4) 86/75 
32 Melasma, pigment disorders 2.01 0.16 0.10 (0.3) 4.97 (4.7) 32/30 
 
 
Q10%a (N) 
Sex Age groups Socioeconomic status Comorbidity 
Male: 8.03 (1686) 18-35: 6.62 (1247) Low: 8.23 (720) None: 7.33 (2573) 
Female: 7.41 (2168) 36-65: 8.10 (1880) Middle: 7.4 (2844) Any: 8.77 (1033) 
 >66: 8.7 (652) High: 8.17 (327)  
Country Belgium Denmark France Germany Hungary Italy  Netherland Norway Poland Russia Spain Turkey UK 
Q10%a (N) 4.2 (250) 6.8 (265) 2.1 (126) 7.2 (290) 6.7 (261) 9.6 (527) 5.6 (235) 9.8 (534) 8.4 (275) 9 (273) 7.4 (274) 4 (270) 6.5 (213) 
 aThe percentage of the mean score of Question10 (therapy issues) relative to the mean total DLQI score:  
𝑚𝑒𝑎𝑛 𝑠𝑐𝑜𝑟𝑒 𝑡𝑜 𝑄𝑢𝑒𝑠𝑡𝑖𝑜𝑛 10
𝑚𝑒𝑎𝑛 𝑡𝑜𝑡𝑎𝑙 𝐷𝐿𝑄𝐼 𝑠𝑐𝑜𝑟𝑒
x100 
bDifferent values due to more missing numbers when regression analysis is performed. cIncluding nail diseases, hyperhidrosis and 
granuloma annulare. dIncluding pyoderma gangrenosum, Behçet’s syndrome, panniculitis, necrobiosis lipoidica. eEffluvium, androgenic 
alopecia, cicatricial alopecia, other hair/scalp conditions. fOther than psoriasis: parapsoriasis, pityriasis rubra pilaris, pityriasis 
lichenoides, pityriasis rosea, Darier’s disease. gStomatitis, glossitis, cheilitis, aphthae. hLichen sclerosus, pruritus/eczema vulvae, scroti et 
ani, balanitis/balanoposthitis. iSkin check of organ transplant recipients, other follow-up or uncertain diagnosis. 
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Table II. Overview of dermatology specific, disease specific and generic instruments assessing quality 
of life with comments on whether the impact of therapy is addressed in the questionnaire. 
 
  
Type and name of instrument 
Therapy 
impact 
Authors, year 
Dermatology specific instruments 
Dermatology Life Quality Index (DLQI) Yes Finlay et al. 1994 (6) 
Skindex, Skindex-29, Skindex-16. Skindex-17 No 
Chren et al. 1996 (28) 
Nijsten et al. 2006 (29)  
Dermatology-Specific Quality of Life (DSQL) No Anderson et al. 1997 (30) 
Dermatology Quality of Life Scales (DQOLS) No Morgan et al. 1997 (31) 
Disease specific instruments 
Psoriasis Disability Index (PDI) Yes Finlay et al. 1987 (32) 
Psoriasis Index of Quality of Life (PSORIQoL) Yes McKenna et al. 2003 (33) 
Rosacea Quality of Life (RosaQuol) Yes Nicholson et al. 2007 (34) 
The Quality of Life Hand Eczema Questionnaire (QOLHEQ) Yes Ofenloch et al. 2014 (35) 
Venous Insufficiency Epidemiological and Economic Study 
(VEINES-QOL) 
Yes Bland et al. 2015 (36) 
Cardiff Acne Disability Index (CADI) No Motley et al. 1992 (37) 
Dermatology-Specific Quality of Life (DSQL) - Contact dermatitis No Anderson et al. 1997 (30) 
Dermatology-Specific Quality of Life (DSQL) - Acne version No Anderson et al. 1997 (30) 
Women with Androgenetic Alopecia Questionnaire (WAA) No Dolte et al. 2000 (38) 
Acne-specific Quality of Life Questionnaire (Acne-QoL) No Martin et al. 2001 (39) 
Psychosomatic Scale for Atopic Dermatitis in Adults (PSS-AD) No Ando et al. 2006 (40) 
Skin Cancer Index (SCI) No Rhee et al. 2006 (41) 
Alopecia Areata Quality of Life (AAQ) No Endo et al. 2012 (42) 
Melasma Quality of Life Scale (MELASQoL) No Lieu et al. 2012 (43) 
The Actinic Keratosis Quality of Life questionnaire (AKQoL) No Esman et al. 2013 (25) 
Alopecia Areata Quality of Life Index (AA-QLI) No Fabbrocini et al. 2013  (44) 
Fragrance Allergy QoL instrument (FQL index) No Heisterberg et al. 2013 (45) 
Vitiligo Quality of Life Index (VitiQoL) No Lilly et al. 2013 (46) 
Autoimmune Bullous Disease QoL Questionnaire (ABQOL) No Sebaratnam et al. 2013 (47) 
Generic instruments* 
Treatment Satisfaction Questionnaire for Medication (TSQM) Yes Atkinson et al. 2004 (4) 
Satisfaction with Medicines Questionnaire (SATMED-Q) Yes Ruiz et al. 2008 (3) 
EuroQol (EQ5D) No EuroQolGroup 1990 (48) 
Medical Outcome Study (MOS) 
MOS Short-Form 36 (SF-36) 
No 
No 
Ware et al. 1992 (49) 
WHOQoL-100 
WHOQoL-BREF 
No 
No 
WHO 1996 (50) 
WHO 1998 (51) 
*Only the most commonly used generic instruments that do not address therapeutic issues are shown here. 
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Figure 1. The percentage of positive answers to having therapy issues (Question 10 of the 
DLQI) for each diagnosis. Diagnoses represented by less than 20 valid answers (hyperhidrosis 
(12), nail diseases (17) and granuloma annulare (13) excluded. 
 
NMSC – Non-melanoma skin cancer 
 
 
  
Percentages of positive answers to Question 10 of the DLQI 
20 
 
E-supplements (3 Tables): 
Supplementary Table I. Participant characteristics. Reproduced with modification from JID 
(Dalgard, Gieler et al. 2015) (7) 
 Patients Controls p-value 
N 4010 1359  
Sex N (%)               Male 1746 (43.7%) 453 (33.4%) p<0.05 
Female 2250 (56.3%) 903 (66.6%) p<0.05 
Age Mean (SD) 47.1 (18) 41.1 (13.6) p<0.05 
Male 48.5 (18.2) 41.1 (14.2) p<0.05 
Female 46.0 (17.8) 41.1 (13.3) p<0.05 
Socioeconomic status 
(self-reported)         Low 723 (18.5%) 215 (15.9%) NS 
Medium 2848 (73.1%) 1012 (75.1%) NS 
High 327 (8.4%) 121 (9%) NS 
 
Comorbidities (any) 1089 (29.1%) 170 (16%) p<0.05 
Cardiological 667 (17.8%) 78 (7.3%) p<0.05 
Respiratory 206 (5.5%) 47 (4.4%) NS 
Diabetes mellitus 224 (6.0%) 24 (2.2%) p<0.05 
Rheumatological 310 (8.3%) 48 (4.5%) p<0.05 
Other 609 (16.3%) 111 (10.4%) p<0.05 
NS – Not significant 
21 
 
 
Supplementary Table II. Frequencies of DLQI scores N = 3846 
DLQI score band 
descriptors (ref. 6, 13) 
Valid % Number 
Cumulative % 
DLQI score 
Extremely large (21-30) 5.2% 200 5.2% > 20 
Very large (11-20) 20.3% 782 25.5% >11 
Moderate (6-10) 19.4% 745 44.9% > 6 
Small (2-5) 26.6% 1023 71.5% > 2 
No (0-1) 28.5% 1096  
Total   3846  
Mean DLQI (SD). N = Valid number of patients 
Sex Male: 6.4 (6.7) N=1686 Female: 7 (6.8) N=2168 
Age groups 
(years) 
18-35: 
7.34 (6.8) N=1247 
36-65: 
6.94 (7) N=1880 
>66: 
5.06 (5.9) N=652 
Socioeconomic 
status 
Low: 
8.22 (7.2) N=720 
Middle: 
6.44 (6.6) N=2844 
High: 
5.88 (5.9) N=327 
Comorbidity None: 6.74 (6.7) N=2573 Any: 6.89 (6.9) N=1033 
BE DK FR GER HU ITa NLD NOb PL RUS ES TR UK 
3.38 
(3.9) 
5.79 
(6.7) 
4.58 
(5.3) 
7.14 
(7.4) 
7.26 
(7.3) 
8.01 
(6.7) 
5.09 
(5.7) 
6.99 
(6.7) 
10.89 
(7.8) 
10.38 
(7.0) 
2.26 
(3.6) 
7.35 
(5.6) 
5.23 
(6.8) 
N=250 265 126 290 261 527 235 534 275 273 274 270 213 
aPadua and Rome 
bOslo and Stavanger 
BE-Belgium DK-Denmark FR-France GER-Germany HU-Hungary IT-Italy NLD-The 
Netherlands NO-Norway PL-Poland RUS-Russia ES-Spain TR-Turkey UK-United Kingdom 
Country (in alphabetical order) Mean DLQI (SD) 
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Supplementary Table III. Distribution by DLQI score band descriptors for each diagnosis and their effect on quality of life (QoL). 
 
 
Diagnosis 
DLQI 
Mean (SD) 
DLQI ≥ 6 (at least 
moderate) % (N) 
DLQI ≥ 11 (at 
least very large) 
Extremely large 
effect on QoL (≥20) 
Very large effect 
on QoL (11-20) 
Moderate effect 
on QoL (6-10) 
Small effect 
on QoL (2-5) 
No effect on 
QoL (0 or 1) 
DLQI score 
descriptor 
Total N=3846 6.73 (6.8) 44.9% (1711) 25.5% (977) 5.2% (200) 20.3% (777) 19.4% (734) 26.6% (988) 28.5% (920) Moderate 
Hidradenitis suppurativa N=46 12.7 (7.6) 80.4% (37) 58.7% (27) 17.4% (8) 41.3% (19) 21.7% (10) 15.2% (7) 4.3% (2) 
Very large 
(11-20) 
Atopic dermatitis N=172 11.53 (7.2) 74.4% (128) 50% (86) 13.4% (23) 36.6% (63) 24.4% (42) 22.7% (39) 2.9% (5) 
Prurigo N=27 11.44 (8.2) 52.9% (17) 48.1% (13) 18.5% (5) 29.6% (8) 14.8% (4) 22.2% (6) 14.8% (4) 
Pruriuts N=60 10.97 (7.1) 74.9% (45) 46.6% (28) 13.3% (8) 33.3% (20) 28.3% (17) 18.3% (11) 6.7% (4) 
Urticaria N=69 9.59 (6.7) 70.9% (49) 40.5% (28) 4.3% (3) 36.2% (25) 30.4% (21) 17.4% (12) 11.6% (8) 
Moderate 
(6-10)h 
Venous leg ulcers N=113 9.45 (7.3) 66.4% (74) 44.3% (49) 8% (9) 35.3% (40) 22.1% (25) 16.8% (19) 17.7% (20) 
Psoriasis N=660 9.14 (7.6) 57.6% (380) 38.8% (256) 9.4% (62) 29.4% (194) 18.8% (124) 24.1% (159) 18.3% (121) 
Genital (non-venereal)a N=32 8.81 (6.4) 65.6% (21) 37.5% (12) 9.4% (3) 28.1% (9) 28.1% (9) 21.9% (7) 12.5% (4) 
Blistering conditions N=66 8.59 (7.4) 54.6% (36) 34.9% (23) 7.6% (5) 27.3% (18) 19.7% (13) 27.3% (18) 18.2% (12) 
 Hand eczema N=156 8.51 (7.2) 55.1% (86) 30.8% (48) 10.3% (16) 20.5% (32) 24.4% (38) 32.7% (51) 12.2% (19) 
Psychodermatological conditions N=34 8.5 (7.1) 57.7% (19) 38.2% (13) 2.9% (1) 35.3% (12) 17.6% (6) 29.4% (10) 14.7% (5) 
Eczema N=241 8.42 (7.2) 54% (130) 36.6% (88) 7.1% (17) 29.5% (71) 17.4% (42) 28.6% (69) 17.4% (42) 
Hyperhidrosis N=12 8.08 (7.6) 50% (6) 33.3 (4) 8.3% (1) 25% (3) 16.7% (2) 25% (3) 25% (3) 
Vasculitis, immunological ulcersb N=67 7.06 (6.1) 52.2% (35) 25.3% (17) 4.5% (3) 20.9% (14) 26.9% (18) 26.9% (18) 20.9% (14) 
Connective tissue disease N=91 7.81 (7.0) 51.7% (47) 30.8% (28) 7.7% (7) 23.1% (21) 20.9% (19) 24.2% (22) 24.2% (22) 
Oral conditionsc N=26 6.77 (6.6) 50% (13) 23.1% (6) 7.7% (2) 15.4% (4) 26.9% (7) 23.1% (6) 26.9% (7) 
Papulosquamous diseasesd N=113 6.37 (6.4) 44.3% (50) 19.5% (22) 7.1% (8) 12.4% (14) 24.8% (28) 28.3% (32) 27.4% (31) 
Othere N=96 6.34 (6.6) 43.8% (42) 24% (23) 4.2% (4) 19.8% (19) 19.8% (19) 24% (23) 32.3% (31) 
Seborrhoeic dermatitis N=75 6.28 (4.4) 52% (39) 16% (12) 0 16% (12) 36% (27) 37.3% (28) 10.7% (8) 
Infections of the skin N=253 6.24 (5.8) 45.4% (115) 22.9% (58) 1.6% (4) 21.3% (54) 22.5% (57) 30.4% (77) 23.1% (61) 
Acne N=234 6.21 (5.2) 40.6% (103) 20.6% (48) 1.4% (3) 19.2% (45) 20% (55) 35.5% (83) 20.5% (48) 
Lichen planus N=46 6.09 (5.4) 48.9% (22) 20% (9) 2.2% (1) 17.8% (8) 28.9% (13) 26.7% (12) 24.4% (11) 
Alopecia areata N=31 5.58 (6.8) 38.7% (12) 16.1% (5) 3.2% (1) 12.9% (4) 22.6% (7) 22.6% (7) 38.7% (12) 
Rosacea N=75 5.37 (5.3) 40% (30) 20% (15) 1.3% (1) 18.7% (14) 20% (15) 25.3% (19) 34.7% (26) 
Small 
(2-5)h 
Scars, skin fibrosis, morphea N=27 5.3 (4.8) 33.2% (9) 18.5% (5) 0 18.5% (5) 14.8% (4) 48.1% (13) 18.5% (5) 
Allergic, drug, phototoxic/-allergic N=24 5.29 (4.3) 41.7% (10) 12.5% (3) 0 12.5% (3) 29.2% (7) 33.3% (8) 25% (6) 
Other hair disordersf N=82 5.01 (5.4) 35.3% (29) 15.8% (13) 2.4% (2) 13.4% (11) 19.5% (16) 31.7% (26) 32.9% (27) 
Melasma, pigment disorders N=32 4.97 (4.7) 40.6% (13) 15.6% (5) 0 15.6% (5) 25% (8) 21.9% (7) 37.5% (12) 
Granuloma annulare N=13 4.0 (2.9) 30.8% (4) 0 0 0 30.8% (4) 46.2% (6) 23.1% (3) 
Nail diseases  N=17 3.88 (4.3) 35.3% (6) 5.9% (1) 0 5.9% (1) 29.4% (5) 17.6% (3) 47.1% (8) 
Vitiligo N=24 3.83 (3.7) 29.2% (7) 4.2% (1) 0 4.2% (1) 25% (6) 33.3% (8) 37.5% (9) 
Malignant melanoma N=86 2.72 (4.4) 15.2% (13) 8.2% (7) 1.2% (1) 7% (6) 7% (6) 30.2% (26) 54.7% (47) 
Benign skin tumours N=159 2.72 (3.7) 18.8% (30) 5% (8) 0 5% (8) 13.8% (22) 24.5% (39) 56.6% (90) 
Non-melanoma skin cancer and AKg  N=401  2.37 (5.0) 13.5% (54) 4% (16) 0.5% (2) 3.5% (14) 9.5% (38) 28.4% (114) 58.1% (233) 
Nevi (91.4% - no or small) N=186 1.52 (2.9) 8.6% (14) 2.7% (5) 0 2.7% (5) 5.9% (11) 18.8% (35) 72.6% (135) 
aLichen sclerosus, pruritus/eczema vulvae, scroti et ani, balanitis/balanoposthitis. bIncluding pyoderma gangrenosum, Behçet’s syndrome, panniculitis, necrobiosis lipoidica. cStomatitis, glossitis, 
cheilitis, aphthae. dOther than psoriasis: parapsoriasis, pityriasis rubra pilaris, pityriasis lichenoides, pityriasis rosea, Darier’s disease. eSkin check of organ transplant recipients, other follow-up, 
or uncertain diagnosis. fEffluvium, androgenic alopecia, cicatricial alopecia, other hair/scalp conditions. gActinic keratosis.  hValues > -.5 rounded upward. Values < -.5 rounded downward. 
